These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1128 related items for PubMed ID: 25894097

  • 1. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y, Liu G, Tong D, Parmar H, Hasenmayer D, Yuan W, Zhang D, Jiang J.
    Prostate; 2015 Aug 01; 75(11):1187-96. PubMed ID: 25894097
    [Abstract] [Full Text] [Related]

  • 2. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
    Yan J, Xie B, Capodice JL, Katz AE.
    Prostate; 2012 Feb 01; 72(3):244-52. PubMed ID: 21656835
    [Abstract] [Full Text] [Related]

  • 3. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.
    Prostate; 2008 May 15; 68(7):793-801. PubMed ID: 18324645
    [Abstract] [Full Text] [Related]

  • 4. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L, Giocanti N, Hennequin C, Favaudon V.
    Prostate; 2010 Mar 01; 70(4):401-11. PubMed ID: 19902473
    [Abstract] [Full Text] [Related]

  • 5. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.
    Prostate; 2012 Jun 01; 72(8):875-85. PubMed ID: 22072572
    [Abstract] [Full Text] [Related]

  • 6. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.
    Prostate; 2008 Jul 01; 68(10):1133-42. PubMed ID: 18454446
    [Abstract] [Full Text] [Related]

  • 7. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S, Agoulnik IU, Weigel NL.
    Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ.
    Carcinogenesis; 2008 Jun 01; 29(6):1148-56. PubMed ID: 18487223
    [Abstract] [Full Text] [Related]

  • 9. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
    Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y.
    Prostate; 2010 Apr 01; 70(5):457-66. PubMed ID: 19902465
    [Abstract] [Full Text] [Related]

  • 10. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X, Gomez-Pinillos A, Liu X, Johnson EM, Ferrari AC.
    Prostate; 2010 Feb 01; 70(2):179-89. PubMed ID: 19790234
    [Abstract] [Full Text] [Related]

  • 11. Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.
    Liu S, Qi Y, Ge Y, Duplessis T, Rowan BG, Ip C, Cheng H, Rennie PS, Horikawa I, Lustig AJ, Yu Q, Zhang H, Dong Y.
    Mol Cancer Ther; 2010 Jul 01; 9(7):2016-25. PubMed ID: 20571066
    [Abstract] [Full Text] [Related]

  • 12. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N, Kawata H, Nishimoto A, Nakamura R, Tsunenari T, Watanabe M, Tachibana K, Shiraishi T, Yoshino H, Honma A, Emura T, Ohta M, Nakagawa T, Houjo T, Corey E, Vessella RL, Aoki Y, Sato H.
    Int J Oncol; 2015 Apr 01; 46(4):1560-72. PubMed ID: 25634071
    [Abstract] [Full Text] [Related]

  • 13. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.
    Shi XB, Xue L, Zou JX, Gandour-Edwards R, Chen H, deVere White RW.
    Prostate; 2008 Dec 01; 68(16):1816-26. PubMed ID: 18780293
    [Abstract] [Full Text] [Related]

  • 14. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
    Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH, Venkateswaran V.
    Prostate Cancer Prostatic Dis; 2012 Dec 01; 15(4):346-52. PubMed ID: 22614062
    [Abstract] [Full Text] [Related]

  • 15. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J.
    Prostate; 2007 Feb 01; 67(2):178-89. PubMed ID: 17044040
    [Abstract] [Full Text] [Related]

  • 16. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
    Madarová J, Lukesová M, Hlobilková A, Riháková P, Murray PG, Student V, Vojtsek B, Kolár Z.
    Neoplasma; 2001 Feb 01; 48(5):419-24. PubMed ID: 11845989
    [Abstract] [Full Text] [Related]

  • 17. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
    Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V, Festuccia C.
    Prostate; 2010 Aug 01; 70(11):1166-78. PubMed ID: 20333699
    [Abstract] [Full Text] [Related]

  • 18. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG, Liu XM, Kreis W, Budman DR.
    Biochem Biophys Res Commun; 1999 May 27; 259(1):21-8. PubMed ID: 10334909
    [Abstract] [Full Text] [Related]

  • 19. Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.
    Zhang Y, Won SH, Jiang C, Lee HJ, Jeong SJ, Lee EO, Zhang J, Ye M, Kim SH, Lü J.
    Pharm Res; 2012 Jun 27; 29(6):1595-608. PubMed ID: 22281759
    [Abstract] [Full Text] [Related]

  • 20. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
    Centenera MM, Carter SL, Gillis JL, Marrocco-Tallarigo DL, Grose RH, Tilley WD, Butler LM.
    Endocr Relat Cancer; 2015 Oct 27; 22(5):805-18. PubMed ID: 26187127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.